Aktis Oncology, Inc.
NASDAQ:AKTS · NASDAQ Global Select
+$0.11 today
Vol 0.55M · Avg 0.33M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
43.6%
avg 62.2%
ROIC
-31.8%
avg -23.2%
ROA
-24.1%
avg -18.5%
Analysis
ROE is currently the strongest return metric at 43.6% versus its period average of 62.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Matthew Roden | President, CEO & Director | $914,680.00 | — | — | — | — |
Akos Czibere | Chief Medical Officer | $676,930.00 | — | 48 | — | — |
Paul L. Feldman | Chief Scientific Officer | $642,415.00 | — | 64 | — | — |
Shulamit Ron-Bigger | Chief Operating Officer | $536,714.00 | — | 45 | — | — |
Patrick A. Baeuerle | Co-Founder & Member of Scientific Advisory Board | — | — | 68 | — | — |
Tyler Benedum | Chief Technical Officer | — | — | 49 | — | — |
Carlos Rodriguez | Executive Director of Corporate Development | — | — | — | — | — |
Kyle D. Kuvalanka | Chief Financial Officer | — | — | 58 | — | — |
Todd Foley | Co-Founder & Chairman | — | — | 54 | — | — |
Dasa Lipovsek | VP & Head of Lead Discovery | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +76.4% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +76.4% (5yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
No competitor data available.
Who manages AKTS?
Aktis Oncology, Inc. (AKTS) lists 10 active executives. The top listed executive is Akos Czibere, Chief Medical Officer.
Are AKTS insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.